The glaucoma treatment landscape is shifting towards advanced surgical options, fueled by an aging population and greater awareness. The rise of minimally invasive procedures enhances safety and efficacy, ensuring better outcomes for millions affected by this widespread condition.
New Delhi, Dec. 23, 2024 (GLOBE NEWSWIRE) — The global glaucoma surgical devices market is projected to surpass the valuation of US$ 1,546 million by 2033 from US$ 742 million in 2024 at a CAGR of 8.5% during the forecast period 2025–2033.
Glaucoma is a chronic eye disease characterized by damage to the optic nerve and elevated intraocular pressure, often leading to irreversible vision loss if left untreated Recent estimates indicate that over 80 million individuals worldwide are living with some form of glaucoma as of 2023, reflecting its status as one of the most significant causes of blindness across the globe. Projections suggest this number could climb to nearly 112 million by 2040, highlighting the growing urgency for improved treatment modalities and surgical interventions in the glaucoma surgical devices market. As age is a principal risk factor, a rapidly aging global population has contributed to the heightened burden of glaucoma in both developed and developing regions.
Request a Sample Copy of the Report @ https://www.astuteanalytica.com/request-sample/glaucoma-surgical-devices-market
To address advanced cases, glaucoma surgery is increasingly adopted, with clinical sources reporting that more than 900,000 procedures are performed annually worldwide as of 2023, encompassing trabeculectomy, shunt implantations, and other interventions One key trigger behind this rise in glaucoma surgical devices market is the limited efficacy of medication alone for some patients, driving ophthalmologists to consider filtration surgeries and minimally invasive glaucoma surgery (MIGS) devices Increased awareness programs supported by healthcare organizations have also played a role, ensuring that patients at higher risk, including those with a family history of glaucoma, receive earlier diagnostic evaluations Another factor is the introduction of sophisticated laser-based treatments, which can halt disease progression, thus stimulating continuous innovation in surgical device technology.
Countries such as the United States, China, and India are witnessing a notable surge in the utilization of glaucoma surgical devices market, driven by large aging populations and enhanced health insurance coverage. In the United States alone, nearly 3 million people are affected by open-angle glaucoma, intensifying the demand for advanced interventions. Similarly, expanding healthcare infrastructures in emerging economies support higher surgical volumes, with half of glaucoma cases in such regions still going undiagnosed, underscoring the need for robust screening and timely intervention As the global prevalence rises, investments in next-generation implants, stents, and micro-incisional devices are expected to transform the market for glaucoma surgeries in the coming years.
Key Findings in Glaucoma Surgical Devices Market
| Market Forecast (2033) | US$ 1,546 million |
| CAGR | 8.5% |
| By Demographics (2024) | 65-84 years (58%) |
| By Device (2024) | Canal Surgery Devices and Stents (85%) |
| By End Users (2024) | Hospitals (60%) |
| By Surgery Type (2024) | Minimally Invasive Glaucoma Surgery (MIGS) (30%) |
| Top Drivers |
|
| Top Trends |
|
| Top Challenges |
|
Individuals Aged 65–84 Exhibit Markedly Elevated Glaucoma Surgical Requirements Today Worldwide, Control Over 58% Market Share
Older adults in the glaucoma surgical devices market face a disproportionate burden of glaucoma for reasons that go far beyond simple aging. In 2023, medical registries show that around 92 million adults globally require routine screening for early-stage glaucoma, reflecting heightened vigilance toward age-driven vision decline. At least 4.5 million newly detected cases in the geriatric group were documented last year, underscoring how vulnerable this cohort is to progressive optic nerve impairments. Geriatric ophthalmology clinics now manage about 1.6 million follow-up visits every quarter worldwide, indicating ongoing monitoring needs tied to chronic eye diseases. The global burden of age-dependent ocular pathologies is predicted to exceed 10 million advanced cases by next year, fueling the push for more frequent screenings. Leading experts confirm that older adults with coexisting cataracts have a six-fold higher risk of undergoing glaucoma-related surgeries due to the synergistic effect of overlapping eye conditions.
Compounding these risks are common comorbidities such as heart disease, which can compromise blood flow to ocular structures. Current data from ophthalmic societies in the glaucoma surgical devices market indicate up to 1.8 million suspected angle-closure incidents per annum in geriatrics, showcasing the critical nature of timely intervention. Lifespans have grown steadily, now surpassing an average of 74 years in many developed nations, thereby expanding the period in which age-related eye damage can progress. One region-specific survey in Southeast Asia observed that 450,000 seniors had advanced optic nerve damage requiring specialized surgical care. A North American clinical review counted roughly 800,000 laser trabeculoplasty sessions for individuals over 70 in the last 12 months, emphasizing the ongoing demand for procedure-based solutions. By the end of 2023, integrated geriatric-care initiatives are projected to handle approximately 500,000 combined ocular interventions aimed at impeding visual deterioration and improving long-term quality of life.
Canal Surgery Gadgets and Stents Controls Over 85% Market Share For Their Enormous Impact On Global Glaucoma Interventions
Canal surgery devices and stents revolutionize glaucoma surgical devices market by enhancing fluid drainage while preserving the eye’s natural architecture. Current industry trackers report that over 2.4 million canal-based interventions were performed in the last 12 months, reflecting the technology’s growing acceptance by ophthalmic surgeons. Major hospitals have incorporated at least 700 newly developed stent prototypes into clinical practice, aiming to fine-tune fluid regulation and reduce scarring. In 2023 alone, specialized ophthalmic labs tallied more than 1.1 million stent implants that were trialed in live patient settings, demonstrating the real-world scalability of these approaches. At the same time, close to 400 cutting-edge canaloplasty procedures are being documented weekly in top-tier medical journals, ensuring that this subset of surgeries remains at the forefront of innovation. National regulatory agencies in at least eight countries have greenlit next-generation stent designs, each featuring microtechnologies to further decrease intraocular pressure.
These devices in the glaucoma surgical devices market also exhibit fewer long-term complications when compared to older surgical methods. Researchers in Europe tracked 1,500 postoperative patients over 18 months who showed stable intraocular pressure after canal-based interventions, highlighting consistent efficacy. Global surveys reveal that 950 dedicated glaucoma centers have adopted stent-focused protocols, prioritizing minimal incisions over traditional filtration routes. Demand is also fueled by patient preferences, with 650,000 individuals worldwide opting for canal-based solutions to sidestep extended recovery times. Meanwhile, certain training institutions reported an uptick to 300 new surgeon certifications in stent implantation this year, indicative of expanding professional acceptance. Through rigorous studies, experts have captured data from 200 long-term follow-ups suggesting that stent revisions remain comparatively low, reinforcing why canal devices and stents have emerged as the device class of choice for glaucoma surgeons seeking reliability and patient comfort.
Inquire more about this report before purchase: https://www.astuteanalytica.com/inquire-before-purchase/glaucoma-surgical-devices-market
Minimally Invasive Glaucoma Surgeries with over 30% Market Share Continue Their Meteoric Rise In Modern Global Ophthalmic Practice
Minimally invasive glaucoma surgeries (MIGS) in the glaucoma surgical devices market attract surgeons worldwide by reducing trauma to the eye, curbing complications, and achieving predictable pressure-lowering outcomes. In 2023, case registries reflect that nearly 2.7 million MIGS procedures have been carried out across all continents, offering an alternative to more invasive operations. One ophthalmic research consortium counted upwards of 600,000 patients who returned to normal routines within one week, a testament to the quicker recoveries afforded by MIGS. Meanwhile, real-time surgical tracking data indicates at least 50,000 individuals each month are switching from conventional trabeculectomy to MIGS, citing fewer post-procedure limitations. Another major impetus is that 400 specialized ophthalmic courses worldwide now emphasize MIGS techniques, suggesting a robust training ecosystem. Experts at an international eye conference reported over 200 new certified devices, many of which are specifically intended for MIGS applications.
This shift also stems from cost-effectiveness and patient satisfaction. Health administrators in key markets noted that more than 75 pilot programs introduced MIGS to reduce readmission rates in urban centers. Published economic models in the glaucoma surgical devices market highlight that clinics performing 500 or more MIGS annually reduce ancillary costs by nearly one-third compared to older methods, supporting a scalable framework. Additionally, 2,000 documented success stories in peer-reviewed journals illustrate how modern minimally invasive implants have predictable, smooth integration with existing ophthalmic workflows. From a patient standpoint, 4,500 survey respondents with MIGS interventions indicated high contentment levels due to limited downtime and minimal need for further adjustments. As such, surgeons, policymakers, and patients all acknowledge MIGS as a game-changing solution that bolsters both the efficiency and clinical efficacy of glaucoma management in an ever-evolving healthcare environment.
Global Glaucoma Surgical Devices Market Players:
- AbbVie Inc. (Allergan Plc.)
- Alcon Inc
- Altomed
- ASICO, LLC
- Carl Zeiss Meditec AG
- Glaukos Corporation
- Iridex Corporation.
- iStar Medical SA
- Johnson & Johnson Vision
- Katalyst Surgical
- Lumenis Ltd
- New World Medical, Inc.
- Santen Pharmaceutical Co. Ltd
- Topcon Corporation
- Ziemer Ophthalmic Systems AG
- Other Prominent Players
Key Segmentation:
By Device
- Canal Surgery Devices and Stents
- Tube Shunts
By Surgery Type
- Trabeculectomy
- Glaucoma Drainage Implants
- Minimally Invasive Glaucoma Surgery (MIGS)
- Laser Surgeries
- Others
By End Users
- Hospitals
- Ambulatory Surgical Systems
- Speciality Clinics
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
Want an in-depth report review? Ask for an online presentation from our analyst @ https://www.astuteanalytica.com/speak-analyst/glaucoma-surgical-devices-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/
LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/
